Live Feeds
● TRACKER Updated 21d ago · 15 sources tracked

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Moderna and Merck have developed an mRNA vaccine called intismeran that reduces the risk of melanoma recurrence. The vaccine passed a Phase 3 trial when used in combination with the drug Keytruda. This development follows a decade of research where the companies navigated pandemic obstacles and logistical challenges. The success has increased Moderna's share price and created potential financial opportunities for five other biotech companies involved in the manufacturing process.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (15)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The mRNA vaccine intismeran reduces the risk of melanoma recurrence.
  • ✓ Moderna and Merck spent a decade overcoming logistical challenges and pandemic-era obstacles to develop the vaccine.
  • ✓ The vaccine was used alongside the drug Keytruda during its successful trial.
🛡️ Source Corroboration: 15 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

The vaccine has officially passed a Phase 3 trial and is used in conjunction with Keytruda.

Live updates

  1. Moderna and Merck mRNA Melanoma Vaccine Passes Phase 3 Trial

    Moderna and Merck have developed an mRNA vaccine called intismeran that reduces the risk of melanoma recurrence. The vaccine passed a Phase 3 trial when used in combination with the drug Keytruda. This development follows a decade of research where the companies navigated pandemic obstacles and logistical challenges. The success has increased Moderna's share price and created potential financial opportunities for five other biotech companies involved in the manufacturing process.

    Why it matters

    Personalized cancer vaccines aim to prevent the return of tumors after initial treatment. This breakthrough suggests mRNA technology can be adapted for oncology beyond infectious diseases.

    What is confirmed

    • The mRNA vaccine intismeran reduces the risk of melanoma recurrence.
    • Moderna and Merck spent a decade overcoming logistical challenges and pandemic-era obstacles to develop the vaccine.
    • The vaccine was used alongside the drug Keytruda during its successful trial.

    Still unconfirmed

    • Five biotech companies stand to profit from every dose of the vaccine manufactured.
    • The vaccine's success led to a surge in Moderna shares.

    What to watch next

    • Regulatory approval filings for intismeran
    • Clinical data on efficacy for other cancer types
    • Manufacturing agreements with the five identified biotech partners
    Sources used for this update (5)
    1. www.statnews.com — Inside Moderna and Merck’s cancer vaccine triumph
    2. consent.yahoo.com — Moderna and Merck Cancer Vaccine Success Is Good News for CancerVax
    3. finance.yahoo.com — Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.
    4. www.usatoday.com — Moderna's personalized cancer vaccine shows promise. Here's why
    5. www.geopop.it — Merck e Moderna annunciano il primo vaccino antitumorale a mRNA che supera la fase 3: come funziona
    confidence 90%

  2. Moderna, Merck melanoma vaccine succeeds in large trial

    Moderna and Merck's mRNA vaccine, tested in a large trial, shows promise in preventing melanoma from returning. The vaccine, known as intismeran, was found to lower the risk of skin cancer recurrence. This breakthrough could potentially usher in a wave of cancer vaccines. The vaccine's success has led to a significant surge in Moderna's shares.

    Why it matters

    The trial's success is a significant development in the fight against cancer, particularly melanoma, a type of skin cancer. The use of mRNA technology, also used in COVID-19 vaccines, is being explored for its potential to treat various types of cancer. The collaboration between Moderna and Merck highlights the importance of partnerships in advancing medical research.

    What is confirmed

    • Moderna shares surge as melanoma vaccine with Merck succeeds in large trial.
    • Moderna and Merck's mRNA vaccine shows promise in preventing melanoma from returning.
    • The vaccine's success could potentially usher in a wave of cancer vaccines.

    What to watch next

    • Further trial results
    • FDA approval process
    • Potential applications in other types of cancer
    Sources used for this update (11)
    1. Reuters — Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
    2. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
    3. The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
    4. CNN — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    5. The Washington Post — Opinion | A cancer vaccine would be a miracle of science — and the free market
    6. The Economist — It now seems possible to vaccinate against cancer
    7. Medical News Today — Melanoma: Personalized vaccine lowers recurrence risk in phase 3 trial
    8. Smithsonian Magazine — A New Personalized Cancer Vaccine Could Keep Skin Cancer From Coming Back, Drugmakers Say
    9. Yahoo Finance — Moderna's 177% Surge Powers a Broad Biotech Rally
    10. Bloomberg.com — A Cancer Vaccine Is Closer Than Ever
    11. www.livemint.com — It now seems possible to vaccinate against cancer
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community